A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting

Samantha Di Donato(Ospedale di Prato Santo Stefano), Laura Biganzoli(Hospital of Prato)

Cancers

June 2, 2021

10.3390/cancers13112762

Cited by 22

Related Papers

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

|Annals of Oncology|2020|1.4k

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

|Annals of Oncology|2018|1.2k

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|322

The requirements of a specialist breast centre

|The Breast|2020|195